EFFICACY OF 0.1% TOPICAL FINASTERIDE SPRAY SOLUTION FOR MALE EYEBROW ENHANCEMENT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPLIT-FACE COMPARATIVE STUDY

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250827008

Enrollment

Registered

2025-08-27

Start date

2025-06-13

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eyebrow hypotrichosis eyebrow hypotrichosis, male eyebrow enhancement, topical finasteride, placebo, split-face study

Interventions

applied 0.1% topical finasteride to one eyebrow and placebo to the contralateral side twice daily for 12 weeks

Placebo Comparator Drug

0.1%finasteride spray solution

Eligibility

Sex/Gender

Male

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are receiving treatment at the dermatology clinic of Mae Fah Luang University Hospital, Bangkok. 2. Male patients aged 18-45 years. 3. Patients with eyebrow hypotrichosis at levels one or two according to the GEBA (Global Eyebrow Assessment) scale. 4. Willing to participate in the research.

Exclusion criteria

Exclusion criteria: 1. Certain diseases or conditions may cause eyebrow hypotrichosis, such as severe or poorly controlled systemic diseases, alopecia areata, trichotillomania, frontal fibrosing alopecia, thyroid disease, hematologic malignancies, revieving chemotherapeutic agents, zinc deficiency, eye diseases, atopic dermatitis, seborrheic dermatitis, lupus erythematosus, scleroderma, leprosy, syphilis, fungal infections and a history of eye and periorbital surgery. 2. Conditions that may interfere with treatment outcomes, such as previous treatments for eyebrow hypotrichosis or hair loss within the past 6 months with Minoxidil, Finasteride, Bimatoprost, antiandrogen, light/laser treatment or eyebrow transplantation. 3. Contraindications for Topical Finasteride for example patients with known hypersensitivity or allergy to finasteride or any of its components, a history of infertility or difficulty fathering children, or a history of varicocele.

Design outcomes

Primary

Measure	Time frame
global photographic assessment 0,4,8,12 week 7 points scale	—

Secondary

Measure	Time frame
hair density, hair diameter, patient satisfaction, adverse effect 0,4,8,12 week folliscope, case record form	—

Countries

Thailand

Contacts

Public Contactbhakinai temnithikul

mae fah luang university

dr.bhakinai@gmail.com026790038

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026